Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
FXR452 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A23105 | 24038130 | Hepatology | Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. | 2014 | Details |
| A23163 | 23994574 | Free Radic Biol Med | Free radical biology for medicine: learning from nonalcoholic fatty liver disease. | 2013 | Details |
| A23168 | 23988487 | Biochem Pharmacol | Bile acid receptors in non-alcoholic fatty liver disease. | 2013 | Details |
| A23313 | 23855299 | J Gastroenterol Hepatol | Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. | 2013 | Details |
| A23496 | 23727264 | Gastroenterology | Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. | 2013 | Details |
| A23539 | 23700488 | PLoS One | Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. | 2013 | Details |
| A23595 | 23651738 | Toxicol Appl Pharmacol | Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction. | 2013 | Details |
| A23759 | 23507574 | Endocrinology | Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis. | 2013 | Details |
| A23805 | 23460643 | J Biol Chem | Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. | 2013 | Details |
| A23887 | 23402081 | Acta Gastroenterol Belg | Pleiotropic functions of bile acids mediated by the farnesoid X receptor. | 2012 | Details |
| A23960 | 23348961 | Gut | Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. | 2013 | Details |
| A24018 | 23299969 | Hepatology | Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. | 2013 | Details |
| A24125 | 23206728 | Prog Lipid Res | Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. | 2012 | Details |
| A24275 | 23057494 | Aliment Pharmacol Ther | Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. | 2012 | Details |
| A24647 | 22652341 | Drug Discov Today | Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. | 2012 | Details |
| A24650 | 22648540 | Histol Histopathol | Farnesoid X Receptor (FXR) from normal to malignant state. | 2012 | Details |
| A25078 | 22187656 | J Lipids | Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. | 2011 | Details |
| A25565 | 21707532 | Mini Rev Med Chem | Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. | 2011 | Details |
| A25723 | 21504366 | Antioxid Redox Signal | Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding. | 2011 | Details |
| A25942 | 21286345 | Hepatol Int | Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. | 2010 | Details |
| A26226 | 20868235 | Biol Chem | Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. | 2010 | Details |
| A26240 | 20847296 | J Lipid Res | Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. | 2010 | Details |
| A26443 | 20460915 | Dig Dis | Bile acids as regulators of hepatic lipid and glucose metabolism. | 2010 | Details |
| A26623 | 20079722 | Chem Biol Interact | Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. | 2010 | Details |
| A27088 | 19195631 | Diabetes Metab | The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. | 2008 | Details |
| A27508 | 18240340 | World J Gastroenterol | The blind men 'see' the elephant-the many faces of fatty liver disease. | 2008 | Details |
| A28625 | 35217809 | Acta Pharmacol Sin | FXR: structures, biology, and drug development for NASH and fibrosis diseases. | 2022 | Details |
| A29086 | 34603061 | Front Pharmacol | Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. | 2021 | Details |
| A29320 | 34256254 | Bioorg Med Chem | Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio. | 2021 | Details |
| A29375 | 34165993 | J Med Chem | Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics. | 2021 | Details |
| A29394 | 34149876 | Exp Ther Med | Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice. | 2021 | Details |
| A29514 | 33959012 | Front Pharmacol | Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling. | 2021 | Details |
| A29742 | 33590776 | Gut Microbes | The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases. | 2022 | Details |
| A30167 | 32875282 | JHEP Rep | Transcriptomic analysis across liver diseases reveals disease-modulating activation of constitutive androstane receptor in cholestasis. | 2020 | Details |
| A30277 | 32712104 | Gastroenterology | FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs. | 2020 | Details |
| A30480 | 32377219 | Nutr Metab (Lond) | Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis. | 2020 | Details |
| A30489 | 32355675 | Hepatobiliary Surg Nutr | Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. | 2020 | Details |
| A30490 | 32355674 | Hepatobiliary Surg Nutr | Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease. | 2020 | Details |
| A30619 | 32097559 | J Chem Inf Model | Computational Insight into the Allosteric Activation Mechanism of Farnesoid X Receptor. | 2020 | Details |
| A30722 | 31909359 | Hepatol Commun | Farnesoid X Receptor Agonism, Acetyl-Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model. | 2019 | Details |
| A31019 | 31388629 | Hepatol Commun | Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. | 2019 | Details |
| A31100 | 31227742 | Sci Rep | Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A31125 | 31201554 | Handb Exp Pharmacol | Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists. | 2019 | Details |
| A31126 | 31201552 | Handb Exp Pharmacol | Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. | 2019 | Details |
| A31513 | 30411084 | Hepatol Commun | FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice. | 2018 | Details |
| A31690 | 30034914 | Liver Res | Bile acid signaling and bariatric surgery. | 2017 | Details |
| A31747 | 29933033 | Pharmacol Ther | Progress and challenges of selective Farnesoid X Receptor modulation. | 2018 | Details |
| A31765 | 29900399 | Data Brief | The effect of synbiotics Bifidobacterium infantis and milk oligosaccharides on shaping gut microbiota community structure and NASH treatment. | 2018 | Details |
| A31816 | 29765319 | Front Pharmacol | Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. | 2018 | Details |
| A31843 | 29717168 | Sci Rep | Allosteric modulation of the farnesoid X receptor by a small molecule. | 2018 | Details |
| A31978 | 29404501 | Hepatol Commun | Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. | 2017 | Details |
| A32073 | 29259742 | ACS Med Chem Lett | Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH. | 2017 | Details |
| A32533 | 28189755 | J Hepatol | Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. | 2017 | Details |
| A32734 | 27652492 | J Med Chem | Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders. | 2016 | Details |
| A33160 | 26579433 | Acta Pharm Sin B | Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration. | 2015 | Details |
| A33468 | 25926979 | F1000Prime Rep | Recent advances in understanding/management of non-alcoholic steatohepatitis. | 2015 | Details |
| A35884 | 19501927 | J Hepatol | Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. | 2009 | Details |
| A36141 | 18948497 | J Pharmacol Exp Ther | Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. | 2008 | Details |
| A36625 | 17588816 | Trends Mol Med | Targeting farnesoid X receptor for liver and metabolic disorders. | 2007 | Details |
| A42377 | 34738233 | J Clin Pharmacol | Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment. | 2022 | Details |
| A42623 | 33985820 | J Hepatol | FXR agonists for NASH: How are they different and what difference do they make? | 2021 | Details |
| A42755 | 33568795 | Nat Rev Gastroenterol Hepatol | The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. | 2021 | Details |
| A43213 | 32275777 | Hepatology | FXR Agonists as Therapy for Liver Disease. | 2020 | Details |
| A43290 | 32050066 | J Chem Inf Model | Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. | 2020 | Details |
| A43319 | 31984784 | Am J Physiol Gastrointest Liver Physiol | Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. | 2020 | Details |
| A43639 | 31237448 | Am J Physiol Endocrinol Metab | Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes. | 2019 | Details |
| A43720 | 31029550 | Bioorg Med Chem | Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists. | 2019 | Details |
| A43726 | 31018107 | Annu Rev Nutr | Bile Acids as Metabolic Regulators and Nutrient Sensors. | 2019 | Details |
| A43783 | 30890204 | Gene Expr | Sterol 12α-Hydroxylase Aggravates Dyslipidemia by Activating the Ceramide/mTORC1/SREBP-1C Pathway via FGF21 and FGF15. | 2019 | Details |
| A44127 | 29651702 | Hepatol Int | Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation. | 2018 | Details |
| A44178 | 29500352 | Cell Death Dis | Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease. | 2018 | Details |
| A44290 | 29142166 | J Toxicol Sci | Fish oil feeding reverses hepatomegaly and disrupted hepatic function due to the lack of FXR signaling. | 2017 | Details |
| A44570 | 28164071 | Ann Pediatr Endocrinol Metab | Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR. | 2016 | Details |
| A44646 | 27822554 | mSystems | Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism. | 2016 | Details |
| A44689 | 27734248 | Dig Dis Sci | FXR Agonists: From Bench to Bedside, a Guide for Clinicians. | 2016 | Details |
| A44726 | 27534992 | J Lipid Res | Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. | 2016 | Details |
| A44774 | 27351453 | Hepatology | G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. | 2016 | Details |
| A44954 | 26628846 | J Clin Exp Hepatol | Intestinal FXR: A New Therapeutic Target for Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A45282 | 25400456 | World J Gastroenterol | GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells. | 2014 | Details |
| A45466 | 24418014 | J Hepatol | Failing FXR expression in the liver links aging to hepatic steatosis. | 2014 | Details |
| A46343 | 19426389 | J Dig Dis | Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. | 2009 | Details |
| A46936 | 33598648 | JHEP Rep | Gut dysbiosis as a driver in alcohol-induced liver injury. | 2020 | Details |
| A46959 | 32404932 | Lab Invest | Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency. | 2020 | Details |
| A46997 | 30803859 | Dig Liver Dis | FXR deficiency alters bile acid pool composition and exacerbates chronic alcohol induced liver injury. | 2019 | Details |
| A47091 | 26305715 | IUBMB Life | Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR signaling in hepatocytes. | 2015 | Details |
| A47097 | 26025474 | Biochimie | Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice. | 2015 | Details |
| A47171 | 24269813 | Biochem Biophys Res Commun | Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. | 2013 | Details |
| A47638 | 34531950 | ACS Med Chem Lett | Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis. | 2021 | Details |
| A47675 | 33839252 | Bioorg Med Chem Lett | Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism. | 2021 | Details |
| A47746 | 32597707 | Am J Physiol Gastrointest Liver Physiol | Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia. | 2020 | Details |
| A47807 | 31494470 | Eur J Med Chem | Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism. | 2019 | Details |
| A47837 | 31144046 | Handb Exp Pharmacol | Targeting Bile Acid-Activated Receptors in Bariatric Surgery. | 2019 | Details |
| A47877 | 30275017 | J Biol Chem | Ligand binding and heterodimerization with retinoid X receptor α (RXRα) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding. | 2018 | Details |
| A47982 | 27425465 | J Steroid Biochem Mol Biol | Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. | 2016 | Details |
| A48003 | 26811456 | Proc Natl Acad Sci U S A | Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. | 2016 | Details |
| A48025 | 26132522 | Future Med Chem | Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. | 2015 | Details |
| A48060 | 25388535 | Curr Top Med Chem | Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation. | 2014 | Details |
| A48066 | 25255039 | J Med Chem | Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. | 2014 | Details |
| A48151 | 21211565 | Pharmacol Res | Tissue-specific function of farnesoid X receptor in liver and intestine. | 2011 | Details |
| A48208 | 19758712 | Trends Pharmacol Sci | Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. | 2009 | Details |